Relay Therapeutics Inc. (RLAY)
Relay Therapeutics Statistics
Share Statistics
Relay Therapeutics has 167.38M shares outstanding. The number of shares has increased by 27.6% in one year.
| Shares Outstanding | 167.38M |
| Shares Change (YoY) | 27.6% |
| Shares Change (QoQ) | 3.03% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 127.16M |
| Failed to Deliver (FTD) Shares | 10 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 15.21M, so 9.09% of the outstanding shares have been sold short.
| Short Interest | 15.21M |
| Short % of Shares Out | 9.09% |
| Short % of Float | 12.28% |
| Short Ratio (days to cover) | 5.71 |
Valuation Ratios
The PE ratio is -1.74 and the forward PE ratio is -1.81. Relay Therapeutics's PEG ratio is 0.11.
| PE Ratio | -1.74 |
| Forward PE | -1.81 |
| PS Ratio | 58.82 |
| Forward PS | 2.9 |
| PB Ratio | 0.76 |
| P/FCF Ratio | -2.34 |
| PEG Ratio | 0.11 |
Enterprise Valuation
Relay Therapeutics Inc. has an Enterprise Value (EV) of 1.4B.
| EV / Earnings | -4.15 |
| EV / Sales | 140.21 |
| EV / EBITDA | -3.77 |
| EV / EBIT | -3.77 |
| EV / FCF | -5.59 |
Financial Position
The company has a current ratio of 15.95, with a Debt / Equity ratio of 0.06.
| Current Ratio | 15.95 |
| Quick Ratio | 15.95 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.87 |
| Cash Flow / Debt | -5.14 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is -45.08%.
| Return on Equity (ROE) | -0.43% |
| Return on Assets (ROA) | -0.39% |
| Return on Capital (ROIC) | -45.08% |
| Revenue Per Employee | 38.34K |
| Profits Per Employee | -1.29M |
| Employee Count | 261 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.67% in the last 52 weeks. The beta is 1.61, so Relay Therapeutics's price volatility has been higher than the market average.
| Beta | 1.61 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 4.3 |
| 200-Day Moving Average | 6.11 |
| Relative Strength Index (RSI) | 35.69 |
| Average Volume (20 Days) | 2.33M |
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.
| Revenue | 10.01M |
| Gross Profit | 10.01M |
| Operating Income | -372.47M |
| Net Income | -337.71M |
| EBITDA | -372.47M |
| EBIT | -372.47M |
| Earnings Per Share (EPS) | -2.36 |
Balance Sheet
The company has 124.29M in cash and 48.5M in debt, giving a net cash position of 75.78M.
| Cash & Cash Equivalents | 124.29M |
| Total Debt | 48.5M |
| Net Cash | 75.78M |
| Retained Earnings | -1.74B |
| Total Assets | 930.12M |
| Working Capital | 818.16M |
Cash Flow
In the last 12 months, operating cash flow was -249.11M and capital expenditures -2.02M, giving a free cash flow of -251.13M.
| Operating Cash Flow | -249.11M |
| Capital Expenditures | -2.02M |
| Free Cash Flow | -251.13M |
| FCF Per Share | -1.76 |
Margins
Gross margin is 100%, with operating and profit margins of -3.72K% and -3.37K%.
| Gross Margin | 100% |
| Operating Margin | -3.72K% |
| Pretax Margin | -3.37K% |
| Profit Margin | -3.37K% |
| EBITDA Margin | -3.72K% |
| EBIT Margin | -3.72K% |
| FCF Margin | -2.51K% |
Dividends & Yields
RLAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -70.24% |
| FCF Yield | -44.65% |
Analyst Forecast
The average price target for RLAY is $18, which is 435.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 435.7% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 1.29 |
| Piotroski F-Score | 2 |